Skip to main content

Advertisement

Table 3 Treatment data and outcome

From: First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis

  Treat-ment time [min] [19] Serum bilirubin [mg/dl] Serum creatinine [mg/dl] Serum BUN [mg/dl] No. of treatments 28d survival
  Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl] Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl] Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl]   
Patient
P1 745 37.4 41.1 25.4 −15.7 0.7 0.8 0.5 −0.3 59 76 28 −48 19 -
P2 800 22.8 24.0 12.8 −11.2 1.0 1.0 0.9 −0.1 26 25 14 −11 10 -
P3 730 20.8 22.3 14.1 −8.2 1.8 1.6 1.5 −0.1 21 20 18 −2 7 -
P4 770 16.3 15.9 13.2 −2.7 2.4 1.9 1.5 −0.4 27 20 18 −2 29 -
P5 800 n.d. 11.6 9.2 −2.4 n.d. 2.8 1.2 −1.6 n.d. 45 13 −32 3 -
P6 600 43.5 41.6 34.2 −7.4 3.9 3.3 2.2 −1.1 91 97 63 −34 22 +
P7 720 3.1 5.3 3.9 −1.4 1.7 3.0 2.1 −0.9 19 33 22 −11 17 +
P8 420 21.6 20.7 17.8 −2.9 1.3 2.0 2.8 +0.8 44 69 82 +13 9 -
P9 570 26.4 26.2 20.3 −5.9 1.9 2.3 1.7 −0.6 43 51 35 −16 6 +
P10 300 1.9 2.0 1.5 −0.5 1.7 1.3 0.7 −0.6 54 31 16 −15 1 -
P11 240 40.4 41.6 29.0 −12.6 3.0 3.2 2.0 −01.2 35 40 27 −13 101 +
P12 510 18.3 17.5 10.9 −6.6 1.4 2.9 2.1 −0.8 40 49 27 −22 3 -
P13 360 38.2 42.1 19.9 −22.2 3.0 2.3 1.2 −1.1 79 68 33 −35 11 +
P14 480 49.3 51.8 35.7 −16.1 3.0 3.0 2.2 −0.8 54 67 39 −28 1 -
Mean ± SD Number [%] 575± 193 26.2± 14.9 26.0± 15.4 17.7± 10.5 −8.3± 6.5 2.0± 0.9 2.2± 0.8 1.6± 0.7 −0.6± 0.6 46± 22 49± 23 31± 20 −18± 16 17± 26 [1–101] 5/14 [36%]
  1. ADVOS advanced organ support
  2. BUN blood urea nitrogen
  3. n.d. not done
  4. Delta absolute changes when comparing values immediately before and after the first ADVOS session
Back to article page